Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

MAP Pharmaceuticals Closes $30 Million Stock Financing

By Pharmaceutical Processing | September 7, 2004

MOUNTAIN VIEW, CA (Sept. 7, 2004) – MAP Pharmaceuticals, Inc., a developer of inhaled drug products, has announced the closing of a $30 million Series B preferred stock financing with several biotechnology investors.

MAP said proceeds from the financing would be used mostly to advance the clinical development of the company’s inhaled drug products for the treatment of asthma and migraine, as well as the Tempo Inhaler platform.

The financing was co-led by three investment firms: Pequot Ventures, the private equity arm of Pequot Capital Management, Inc., Bay City Capital and Skyline Ventures. The Perseus-Soros Biopharmaceutical Fund, the founding investor in MAP, also was a significant investor in this round, MAP said.

With the closing of the financing, Patrick Enright of Pequot Capital Ventures, Carl Goldfischer of Bay City Capital and John Freund of Skyline Ventures will join MAP’s board. Steve Elms and Anthony Sun of Perseus-Soros Biopharmaceutical Fund, Gerri Henwood, chief executive officer of Auxilium Pharmaceuticals, Michael McCord of McCord Investments and Thomas Armer, president of MAP, remain on the board.

MAPs’ lead product candidate, which is scheduled to enter Phase II clinical trials this fall, is a nebulized form of budesonide, a steroid currently used to treat pediatric asthma. MAP also is developing the Tempo Inhaler, a pressurized metered dose inhaler.

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE